Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis

Abstract

The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin α v β 5 antagonists. The α v β 5 -mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of α v β 5 -mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing α v β 5 antagonists.

1 - 48 . (canceled)  
     
     
         49 . A method for inhibiting α v β 5  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis inhibiting amount of an α v β 5  antagonist, wherein said antagonist comprises a matrix metalloproteinase polypeptide or an active fragment thereof.  
     
     
         50 . The method of  claim 50 , wherein said antagonist consists essentially of the matrix metalloproteinase polypeptide or an active fragment thereof.  
     
     
         51 . The method of  claim 50 , wherein the matrix metalloproteinase polypeptide comprises an amino acid sequence shown in SEQ ID NOs: 11-22.